From a therapeutic perspective, the above findings suggest that inhibition of ADAR1 has potentially desirable therapeutic outcomes for at least most cancers, and that loss of ADAR1 activates ZBP1-mediated cell necroptosis, which may be a worthwhile therapeutic modality to try in the context of cancer. The gene discussed is ZBP1; the disease is cancer.